Susceptibility of Escherichia coli to the amoxycillin-clavulanate combination: which recommendations should be used to provide relevant information to clinicians?

Clin Microbiol Infect. 2005 Mar;11(3):237-40. doi: 10.1111/j.1469-0691.2005.01075.x.

Abstract

This study compared MIC distributions of amoxycillin-clavulanate obtained with NCCLS and French (Comite de l'Antibiogramme de la Societe Francaise de Microbiologie; CA-SFM) methodologies for Escherichia coli isolates from urine that were non-susceptible to amoxycillin-clavulanate by the disk diffusion method. With the NCCLS and CA-SFM methods, 74% and 13%, respectively, of these isolates were susceptible to amoxycillin-clavulanate. Therefore, the apparent relatively poor efficacy of amoxycillin-clavulanate against E. coli in French hospitals probably reflects a methodological difference rather than a localised resistance problem. This implies that amoxycillin-clavulanate could be used as an alternative to fluoroquinolones for treatment of E. coli urinary tract infections. Susceptibility tests for amoxycillin-clavulanate should be standardised worldwide.

MeSH terms

  • Amoxicillin-Potassium Clavulanate Combination / pharmacology*
  • Drug Resistance, Bacterial
  • Escherichia coli / drug effects*
  • Escherichia coli Infections / microbiology
  • Guidelines as Topic
  • Humans
  • Microbial Sensitivity Tests / methods*
  • Urinary Tract Infections / microbiology

Substances

  • Amoxicillin-Potassium Clavulanate Combination